Gemcitabine, an anticancer agent, is currently in clinical use for the treatment of several types of cancer. Unfortunately, gemcitabine is rapidly metabolised with a short plasma half-life and its cytostatic action is strongly exposure-time dependent. In order to achieve the required concentration over sufficient periods of time, repeated application of relatively high doses is required. This, in ...